Reference table
Which peptides in this index are actually approved drugs?
The answer
Three, and their approvals are narrow: an approval belongs to a product in a stated indication, not to a molecule in every use a seller can imagine for it.
An FDA approval means a specific product completed clinical development — controlled trials in a named indication, a reviewed manufacturing process, and labeling that states what the evidence supports. It is the strongest position a molecule in this index can hold, and it is also the narrowest, because it attaches to a product and an indication rather than to a compound in general.
The consequence for supply is direct. Under section 503A a pharmacy may not compound what is essentially a copy of a commercially available drug unless a prescriber documents a clinical difference for an individual patient, and the FDA has rejected price as such a difference.
Denominator
The rows are the molecules this index files as approved. Where this index's ledger carries no dated approval entry for a product, the record column says so rather than supplying a year; the approved-product column states the products the ledger names.
Rows are read from MOLECULES[] where status is approved, MOLECULES[].approvedProduct, MOLECULES[].route, MOLECULES[].record[] entries stating an approval — the same dated ledger the molecule index renders. No cell on this page is typed by hand.
| Molecule | Approved product | Route | Approval record in this index |
|---|---|---|---|
| Tesamorelin | EGRIFTA WR (2025); EGRIFTA (2010) | Subcutaneous injection | November 2010. FDA approves tesamorelin (EGRIFTA) for the reduction of excess abdominal fat in adults with HIV and lipodystrophy. March 2025. FDA approves EGRIFTA WR, an eight-fold concentrated formulation reconstituted weekly rather than daily; it replaces EGRIFTA SV. |
| Semaglutide | Ozempic, Wegovy, Rybelsus | Subcutaneous injection; oral (Rybelsus) | April 2026. FDA proposes excluding semaglutide from the 503B bulks list, closing the outsourcing-facility route; patient-specific 503A compounding requires a documented clinical need an approved product cannot meet. |
| Tirzepatide | Mounjaro, Zepbound | Subcutaneous injection | this index's ledger carries no dated approval entry for this product |
The approved page states where compounded copies of these products now stand, and the GLP-1 receptor agonists page covers the class where 2026's supply-side changes cut hardest.
Other tables
Monographs in this table